This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Penumbra (PEN) Q4 Earnings Lag Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Penumbra (PEN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Lags Q3 Earnings Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 10.53% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line
by Zacks Equity Research
Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Penumbra (PEN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 145.45% and 10.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Until we have nano-bots to cruise our blood vessels, the catheter remains mightier than the scalpel
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
5 MedTech Outperformers With Nearly 40% or More Gain in 2021
by Debanjana Dey
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.
Strong U.S. Housing Demand: Global Week Ahead
by John Blank
The end of calendar Q1 brings us new Case-Shiller data, a new OPEC+ meeting, and a giant cargo ship still blocking the Suez Canal.
Here's Why You Should Retain Integra LifeSciences (IART) Stock
by Zacks Equity Research
Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.
Encompass Health (EHC) Opens Hospital, Boosts Texas Presence
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Texas, which reinforces the company's efforts to broaden presence in the state.
The Zacks Analyst Blog Highlights: Interactive Brokers, Etsy and Penumbra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Interactive Brokers, Etsy and Penumbra
Top Stock Picks for Week of March 29, 2021
by Panel Of Zacks Experts
Top Picks for Investors Interested in the Shipping and Medical Space.
Has Penumbra (PEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Buy These 5 Low-Beta Stocks & Combat the Choppy Market
by Nilanjan Banerjee
Low-beta stocks may be able to help sail through the choppy market conditions.
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day